Subscribe
Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

JAMA Editor’s Summary

Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
December 22, 2020
ADVERTISEMENT
EHRGo-THE FUTURE OF HEALTHCARE EDUCATION

Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 22/29, 2020 issue

ADVERTISEMENT
EHRGo-THE FUTURE OF HEALTHCARE EDUCATION

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Hera Diagnostics is eradicating cervical cancer in developing communities Teo Tijerina is the CEO of Hera Medical Devices, a cancer diagnostics startup currently focusing on bringing a cervical cancer screening tool to market.